The largest U.S. banks are scrutinizing members of the Federal Reserve for any insight into how the central bank will tinker interest rates.Banksread more
Facebook's cryptocurrency project has already been met with skepticism from policymakers around the world.Technologyread more
The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
Stone, 66, a notorious Republican political operative who has described himself as a "dirty trickster," had previously been dressed down by the judge for his public remarks...Politicsread more
The Biden team's second-quarter Federal Election Commission filing shows that the campaign wrote a check of just over $5,300 on June 28 to Sheehan Associates for "strategic...2020 Electionsread more
See which stocks are posting big moves after the bell on July 16.Market Insiderread more
While the vote served as a show of solidarity for Democrats, it recommended no substantive penalty against Trump.Politicsread more
United Airlines' second-quarter profit tops estimates but questions about the 737 Max linger.Airlinesread more
Three civil rights groups filed a federal lawsuit on Tuesday challenging the Trump administration's new asylum rule, which bars asylum claims from most noncitizens who travel...Politicsread more
Google VP of policy Karan Bhatia started sweating early as hearing chair Ted Cruz brings out an internal presentation created within the company.Technologyread more
At a hearing with the House Judiciary subcommittee on antitrust, an Amazon representative disputed a key argument about how it users sellers' data.Technologyread more
Shares of Bristol-Myers Squibb fell 7% Monday after the pharmaceutical giant announced that the proposed acquisition of Celgene will now close later than originally expected and will involve a divestiture of Celgene's psoriasis drug.
In a Securities and Exchange Commission filing, the company said it now expects to close the planned $74 billion deal by the end of 2019 or beginning of 2020. It had originally expected to close the acquisition by the third quarter.
Celgene's stock also dropped 5%.
Bristol-Myers Squibb said that the divestiture of the drug Otezla would be used to help the company decrease financial leverage after the merger. Otezla generated about $1.6 billion in revenue last fiscal year for Celgene, according to a securities filing.
Bristol-Myers Squibb announced the acquisition in January but has not yet received approval from the Federal Trade Commission.
"Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene. The company is focused on realizing the promise of the transaction, and is continuing to work to complete the transaction on a timely basis," the company said in a securities filing.
Shareholders of both companies had previously approved the deal.